Nebraska Cannabis Wins 7-0 in Court. The Next Bottleneck Is a License

On September 4, 2026, Crista Eggers’s name appeared in another decision from the Nebraska Supreme Court in Lincoln. This time, the ballot campaign she helped sponsor survived. The court affirmed the judgment rejecting a challenge to the signatures behind Nebraska’s two medical cannabis initiatives. For Eggers, executive director of Nebraskans for Medical Marijuana, the result moved the argument from whether the laws could stand toward whether the state would make them work. (S1, S2)

Her name was in the case because she was more than a public advocate. Eggers, Anna Wishart and Adam Morfeld were the sponsors defending the petition effort. Former state Senator John Kuehn had sued before the November 2024 election; Secretary of State Robert Evnen joined the litigation with his own challenge. By the time the appeal was decided, voters had already adopted the measures and regulators were building a licensing system beneath them. (S1)

Chief Justice Jeffrey Funke wrote the court’s principal opinion in a unanimous result. The decision preserved the lower court’s finding that the petitions contained enough valid signatures. It did not award a dispensary license, approve a new fee schedule or set a first-sale date. Those distinctions now define the business story: Nebraska’s legal foundation has survived this challenge, while the machinery needed to turn that foundation into patient access remains a separate undertaking. (S1, S3)

The next scheduled Medical Cannabis Commission meeting is September 14, at 301 Centennial Mall South in Lincoln. The commission has already advanced proposed amendments and fees into formal rulemaking. Its own explanation says that vote does not make the proposals effective. (S3, S4)

“Today, our state’s highest court stated the obvious: they cannot.”

— Crista Eggers, executive director, Nebraskans for Medical Marijuana; statement reported by Nebraska Examiner (S2)

Kuehn’s challenge was consequential because each petition needed 86,499 valid signatures. The issue was not simply whether wrongdoing occurred anywhere in the campaign. It was whether the evidence justified invalidating enough signatures to make either petition legally insufficient. That was the bridge the challengers tried to build. (S1)

Lancaster County District Judge Susan Strong found problems with some signatures but held that the challengers fell short. Her judgment left 89,251 valid signatures on the legalization petition and 89,030 on the regulatory petition. Subtracting the threshold leaves respective margins of 2,752 and 2,531. The Supreme Court affirmed that judgment. (S1)

The dispute turned in part on the difference between a petition circulator and a notary. A circulator collects signatures and makes an affidavit about that work. A notary authenticates the affidavit. Kuehn and Evnen sought broader consequences from improper notarizations, relying on a line of reasoning associated with the court’s 1919 decision in Barkley v. Pool. The Supreme Court declined to automatically carry a defective notarization across other pages handled by the same notary. (S1)

That leaves a narrower result than either a sweeping blessing of the campaign or a declaration that petition safeguards do not matter. The court examined the evidence and the standards for removing signatures’ presumption of validity. It upheld Strong’s handling of the particular claims before her. The legal protection belonged to signatures that had not been sufficiently discredited; it was not immunity for every act performed during the petition drive. (S1)

Justice William Cassel made that limit explicit in a concurrence joined by Justice John Freudenberg. Sufficient evidence of pervasive notarial failure, or participation in fraud, could require sponsors to prove affected signatures were valid, Cassel reasoned. He agreed that this record did not establish that level of failure. His concurrence matters because it preserves an election-integrity argument without accepting the challengers’ proposed outcome in this case. (S1)

Justice Stephanie Stacy raised a different issue in her separate concurrence: whether the court should revisit older precedents permitting certain petition-validity challenges to continue after an election through declaratory litigation. She agreed with the judgment while questioning the procedural route. The opinions therefore close this appeal with agreement on the result and different concerns about how future ballot litigation should proceed. (S1)

Attorney General Mike Hilgers rejected the court’s reasoning in his public response but said his office would comply. Eggers framed the decision as a limit on officials’ ability to override voters. Their disagreement is real; so is the distinction between it and the court’s actual holding. The justices resolved the petition-signature case. They did not adjudicate every future dispute over how Nebraska regulates medical cannabis. (S1, S2)

That distinction has a history. When Governor Jim Pillen certified the two measures in December 2024, a joint statement from his office and Hilgers’s office acknowledged their enactment while reserving concerns about federal law and the Nebraska Constitution. The signature ruling addresses only one part of that earlier statement. It removes a specific threat to the laws and leaves implementation questions to their own proceedings. (S1, S5)

Nebraska’s regulatory statute places authority over the registered medical cannabis system with the commission. A business therefore needs more than confidence in the ballot result. It needs an available license category, an application period, an approval and compliance with the requirements for its operation. The commission’s application page treats cultivation, manufacturing, transportation and dispensing separately. That separation helps explain why a legal victory cannot, by itself, produce a finished retail supply chain. (S6, S7)

The commission’s current permanent regulations completed review with Hilgers’s approval on June 30 and Pillen’s approval on July 1, 2026, according to the agency. The newer package advanced on August 17 remains proposed. The agency specifically says licenses continue under the existing six-month renewal structure until the changes become effective. Calling the August vote a completed licensing overhaul would erase the very step that applicants are still waiting for. (S3)

The proposed text illustrates the commercial choices inside that process. It includes a $5,000 application fee for cultivators, with a refund available if an applicant withdraws before the deadline and no refund after that point. It also links license duration to whether an application or renewal fee is required. The agency cannot collect the proposed fees before adoption. They show why timing and working capital belong in the same conversation. (S8)

The commission explains that the Legislature authorized fees of up to $50,000 per fee in April. That statutory ceiling is not a statement that every applicant owes $50,000. The agency must still adopt a particular schedule through rulemaking, obtain the required reviews and approvals, and reach the effective date. Confusing the ceiling with a bill due would exaggerate an operator’s immediate obligation while obscuring the actual uncertainty about when a new schedule begins. (S3)

The existing regulations also determine what a Nebraska dispensary could eventually put on its shelves. They allow forms including tablets, capsules, tinctures, topical preparations and patches. They exclude raw plant material and products administered by smoking, combustion or vaping. A storefront plan copied from a flower-heavy adult-use market would therefore miss a basic feature of Nebraska’s permitted product mix. This is a question of the state’s rules, not a claim about which form works medically. (S9)

Cultivation has constraints of its own. The current text sets a baseline maximum of four cultivator licenses and allows a possible additional license in a following year if the commission finds demand requires it. It also caps flowering plants at 1,250 for the facility configurations described in the rules. Those limits shape the potential upstream market, but they do not establish how much finished medicine will be available or when it will reach a dispensary. (S9)

The application website offers another reason to avoid treating headlines as an operating calendar. Its manufacturing section still displays an August 17 deadline, while other portions retain older descriptions of the program. The separate rules page is explicit about the current and proposed packages. Where government pages describe different stages, the responsible conclusion is limited: a new retail opening date has not been verified in an operative licensing notice. (S3, S7)

Cannabis Inc has followed a similar separation between legal authorization and actual supply in Alabama, where the first medical sales arrived years after the underlying law. Nebraska has its own statutes and timeline. The useful comparison is the sequence of work: permission in law must be followed by licensed production, finished products and a place where a patient can obtain them.

The September 14 meeting is the next public opportunity to see that sequence advance. The commission’s published event notice supplies a time and location, not a promise to approve a particular business. The separate rulemaking process includes public comment, consideration of changes and review by the attorney general and governor. An investor’s calendar will become firmer when those steps produce decisions and effective dates, rather than simply another proposed document. (S3, S4)

Eggers’s September 4 response returned to patient access. The court had resolved the argument over whether the petitions contained enough valid signatures; the campaign still wanted the state to deliver a functioning program. That is the unfinished part of the victory. The names on the petitions survived their test in Lincoln. What patients can eventually buy will depend on the decisions that follow. (S1, S2)

Keep Reading

Policy & Compliance

Josh Turek Calls for Legal, Taxed Cannabis in Iowa’s U.S. Senate Race

His opponent, Ashley Hinson, voted against federal legalization but backed banking reform. As Iowa expands its medical program, the race reveals three different paths for cannabis businesses, and no single promise that delivers them all.

By Cannabis Inc, Editorial Staff·7 min read

Policy & Compliance

Georgia Wants USPS to Deliver Medical Cannabis. The Postal Service's Rulebook Has a Catch

Regulators say April's Schedule III order lets the state's 18 dispensaries ship to 45,000 patients by certified mail, with a vote set for Sept. 30. But USPS Publication 52 still requires a DEA registrant on both ends of a controlled-substance package, and a 2021 rule bars vapes from the mail entirely.

By Cannabis Inc, Editorial Staff·7 min read